Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293145 | 0.84 | CES2 (0.55) | CES2CES1HCAR1HDAC1HDAC6 | |
| SCHEMBL114867 | 0.84 | CES2 (0.62) | CES2CES1HCAR1HDAC1HDAC6 | |
| SCHEMBL347092 | 0.84 | TPMT (0.59) | TPMTHCAR1HPGDHCAR2PARP1 | |
| SCHEMBL4360630 | 0.84 | TPMT (0.52) | CES2CES1TPMTHCAR1HDAC6 | |
| SCHEMBL765387 | 0.80 | CES2 (0.46) | CES2CES1TPMTHCAR1HDAC3 | |
| SCHEMBL1056148 | 0.80 | TPMT (0.70) | CES2CES1TPMTHCAR1SMN1; SMN2 | |
| SCHEMBL879166 | 0.80 | CES2 (0.46) | CES2CES1TPMTHCAR1HDAC3 | |
| SCHEMBL2468003 | 0.78 | PARP1 (0.50) | CES2CES1TPMTHCAR1HDAC3 | |
| SCHEMBL10417659 | 0.78 | CES2 (0.34) | CES2CES1TPMTHDAC3HDAC1 | |
| SCHEMBL24710981 | 0.77 | CES2 (0.54) | CES2CES1TPMTHCAR1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843521-A | Compound serving as thyroid hormone beta receptor agonist as well as preparation method and application thereof | 中国药科大学 | 2024-04-09 | — | — | CN | disclosed |
| WO-2022129047-A2 | NOVEL MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129047-A2 | NOVEL MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| US-20180148410-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2018-05-31 | — | — | US | disclosed |
| EP-2371930-B1 | A blue phase liquid crystal composition | SONY CORP (JP) | 2014-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148410-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | GLI1, SHH, HRAS | CES2 1397/4885CES1 863/4885TPMT 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.